JP2004535441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004535441A5 JP2004535441A5 JP2003508349A JP2003508349A JP2004535441A5 JP 2004535441 A5 JP2004535441 A5 JP 2004535441A5 JP 2003508349 A JP2003508349 A JP 2003508349A JP 2003508349 A JP2003508349 A JP 2003508349A JP 2004535441 A5 JP2004535441 A5 JP 2004535441A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dihydroxyvitamin
- cancer
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 210000004027 cells Anatomy 0.000 claims 7
- 239000002254 cytotoxic agent Substances 0.000 claims 7
- 231100000599 cytotoxic agent Toxicity 0.000 claims 6
- 230000001028 anti-proliferant Effects 0.000 claims 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 4
- 229940046008 Vitamin D Drugs 0.000 claims 4
- 229930003316 Vitamin D Natural products 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 235000019166 vitamin D Nutrition 0.000 claims 4
- 239000011710 vitamin D Substances 0.000 claims 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 4
- 206010006007 Bone sarcoma Diseases 0.000 claims 3
- 206010024324 Leukaemias Diseases 0.000 claims 3
- 210000004698 Lymphocytes Anatomy 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010025650 Malignant melanoma Diseases 0.000 claims 3
- 206010025310 Other lymphomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 230000002708 enhancing Effects 0.000 claims 3
- 230000003211 malignant Effects 0.000 claims 3
- 208000009018 medullary Thyroid cancer Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000009251 multiple myeloma Diseases 0.000 claims 3
- 201000000582 retinoblastoma Diseases 0.000 claims 3
- 210000004881 tumor cells Anatomy 0.000 claims 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 210000003128 Head Anatomy 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 210000003739 Neck Anatomy 0.000 claims 2
- 210000000496 Pancreas Anatomy 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 2
- 210000003932 Urinary Bladder Anatomy 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 230000001946 anti-microtubular Effects 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 230000003115 biocidal Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- FPCVFWSJHMLPDB-UHFFFAOYSA-N 2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-4-fluoropentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CC(F)C(O)=O)C(O)=O)C=C1 FPCVFWSJHMLPDB-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 208000009956 Adenocarcinoma Diseases 0.000 claims 1
- 229940009456 Adriamycin Drugs 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- 210000003679 Cervix Uteri Anatomy 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 229960000975 Daunorubicin Drugs 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 229960000908 Idarubicin Drugs 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960004857 Mitomycin Drugs 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 claims 1
- 208000000649 Small Cell Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 210000004291 Uterus Anatomy 0.000 claims 1
- 229960003048 Vinblastine Drugs 0.000 claims 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229960004528 Vincristine Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 230000002357 endometrial Effects 0.000 claims 1
- 229960004750 estramustine phosphate Drugs 0.000 claims 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical group ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- 229940027318 hydroxyurea Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- 229960004694 prednimustine Drugs 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 102000009310 vitamin D receptors Human genes 0.000 claims 1
- 108050000156 vitamin D receptors Proteins 0.000 claims 1
Claims (25)
1α,24(S)-ジヒドロキシビタミンD2 を含有することを特徴とする悪性細胞又は腫瘍細胞の異常増殖の抑制用医薬組成物であって、前記細胞が肺、首及び頭部、膵臓、子宮内膜、膀胱、頸部、卵巣の癌、扁平上皮癌、ミエロイド及びリンパ球白血病、リンパ腫、髄様甲状腺癌、メラノーマ、多発性ミエローマ、網膜芽腫又は軟組織及び骨の肉腫である、前記医薬組成物。
1α,24(S)-ジヒドロキシビタミンD2を含有することを特徴とする悪性細胞又は腫瘍細胞の異常増殖活性の抑制用医薬組成物であって、前記細胞が肺、首及び頭部、膵臓、子宮内膜、膀胱、頸部、卵巣の癌、扁平上皮癌、ミエロイド及びリンパ球白血病、リンパ腫、髄様甲状腺癌、メラノーマ、多発性ミエローマ、網膜芽腫又は軟組織及び骨の肉腫である、前記医薬組成物。
1α,24(S)-ジヒドロキシビタミンD2を毎日の投薬養生又はエピソード投薬養生で投与する形態にある、請求項２記載の医薬組成物。
エピソード養生が２〜７日毎に１回の投薬である、請求項３記載の医薬組成物。
1α,24(S)-ジヒドロキシビタミンD2を約10〜100μg/日の用量で毎日投与する形態にある、請求項３記載の医薬組成物。
1α,24(S)-ジヒドロキシビタミンD2を経口投与し、静脈内投与し、癌部位に直接注射し、又は癌部位に位置送出する形態にある、請求項２記載の医薬組成物。
1α,24(S)-ジヒドロキシビタミンD2を経口投与する形態にある、請求項６記載の医薬組成物。
1α,24(S)-ジヒドロキシビタミンD2を細胞傷害薬と同時投与する形態にある、請求項２記載の医薬組成物。
細胞傷害薬が抗代謝薬、及び抗微小管薬、アルキル化剤、白金薬剤、アントラサイクリン、トポイソメラーゼインヒビター、又は抗生物質である、請求項８記載の医薬組成物。
抗代謝薬が5-フルオロ-ウラシル、メトトレキセート又はフルダラビンである、請求項９記載の医薬組成物。
抗微小管薬がビンクリスチン、ビンブラスチン又はタキサンである、請求項９記載の医薬組成物。
タキサンがパクリタキセル又はドセタキセルである、請求項１１記載の医薬組成物。
アルキル化剤がシクロファスファミド、メルファラン、バイオコロエチルニトロソ尿素又はヒドロキシ尿素である、請求項９記載の医薬組成物。
白金薬剤がシスプラチン、カルボプラチン、オキサリプラチン、JM-216又はCI-973である、請求項９記載の医薬組成物。
アントラサイクリンがドクスルビシン又はダウノルビシンである、請求項９記載の医薬組成物。
抗生物質がミトマイシン、イダルビシン、アドリアマイシン又はダウノマイシンである、請求項９記載の医薬組成物。
トポイソメラーゼインヒビターがエトポシド又はカンプトセシンである、請求項９記載の医薬組成物。
細胞傷害薬がエストラムスチンホスフェート又はプレドニムスチンである、請求項９記載の医薬組成物。
細胞傷害薬の抗増殖有効量が単独で投与される場合の細胞傷害薬の抗増殖有効量より低い、請求項８記載の医薬組成物。
1α,24(S)-ジヒドロキシビタミンD2を含有することを特徴とする、膵臓癌、子宮内膜癌、肺の小細胞癌及び非小細胞癌（扁平細胞型、腺癌型及び大細胞型を含む）、頭部及び首の扁平細胞癌、膀胱癌、卵巣癌及び頸癌、ミエロイド及びリンパ球白血病、リンパ腫、肝臓腫瘍、髄様甲状腺癌、多発性ミエローマ、メラノーマ、網膜芽腫又は軟組織及び骨の肉腫の病的作用を軽減するため医薬組成物。
1α,24(S)-ジヒドロキシビタミンD2を含有することを特徴とする細胞傷害薬の抗増殖効果増進剤。
1α,24(S)-ジヒドロキシビタミンD2を細胞傷害薬の投与の0.5〜７日前に投与する形態にある、請求項２１記載の抗増殖効果増進剤。
1α,24(S)-ジヒドロキシビタミンD2を細胞傷害薬の投与の２〜４日前に投与する形態にある、請求項２２記載の抗増殖効果増進剤。
1α,24(S)-ジヒドロキシビタミンD2を含有することを特徴とする、悪性細胞又は腫瘍細胞の分化を誘発剤。
1α,24(S)-ジヒドロキシビタミンD2 を含有することを特徴とする、ビタミンＤ受容体を発現する腫瘍を有する被験者の治療用医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/891,963 US6538037B2 (en) | 1991-01-08 | 2001-06-26 | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
| PCT/US2002/020317 WO2003002110A1 (en) | 2001-06-26 | 2002-06-26 | METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D¿2? |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004535441A JP2004535441A (ja) | 2004-11-25 |
| JP2004535441A5 true JP2004535441A5 (ja) | 2006-01-05 |
Family
ID=25399131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003508349A Pending JP2004535441A (ja) | 2001-06-26 | 2002-06-26 | １α，２４（Ｓ）−ジヒドロキシビタミンＤ２の調製方法及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6538037B2 (ja) |
| EP (1) | EP1408939A4 (ja) |
| JP (1) | JP2004535441A (ja) |
| KR (1) | KR20040011559A (ja) |
| CN (1) | CN1520288A (ja) |
| AU (1) | AU2002315463B2 (ja) |
| CA (1) | CA2451039A1 (ja) |
| IL (1) | IL159067A0 (ja) |
| MX (1) | MXPA03011306A (ja) |
| WO (1) | WO2003002110A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009958A1 (en) * | 1991-01-08 | 2004-01-15 | Bone Care International, Inc. | Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2 |
| US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
| US20020128240A1 (en) * | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
| US6503893B2 (en) * | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US6566353B2 (en) * | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
| US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| CA2326117A1 (en) * | 1998-03-27 | 1999-10-07 | Oregon Health Sciences University | Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders |
| HUP0501186A2 (en) * | 2001-12-03 | 2006-05-29 | Novacea | Pharmaceutical compositions comprising active vitamin d compounds |
| US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| US20040058895A1 (en) * | 2002-09-18 | 2004-03-25 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
| US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
| US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US20050222190A1 (en) * | 2004-03-30 | 2005-10-06 | Curd John G | 1,4-bis-N-oxide azaanthracenediones and the use thereof |
| US7094775B2 (en) * | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| EP1812011A1 (en) * | 2004-11-12 | 2007-08-01 | Bioxell S.p.a. | Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer |
| US20100009949A1 (en) * | 2006-03-24 | 2010-01-14 | Bioxell S.P.A. | Novel method |
| CN109627279A (zh) * | 2019-02-01 | 2019-04-16 | 浙江花园营养科技有限公司 | 一种活性维生素d3中间体的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670190A (en) | 1973-01-10 | 1987-06-02 | Hesse Robert H | 1-α-hydroxy vitamin D compounds and process for preparing same |
| US3880894A (en) | 1974-05-24 | 1975-04-29 | Wisconsin Alumni Res Found | 1,25-Dihydroxyergocalciferol |
| US4022891A (en) | 1974-06-18 | 1977-05-10 | Teijin Limited | Novel 1α,24-dihydroxycholecalciferol compositions, novel precursors thereof, and processes for preparing them |
| GB1583749A (en) | 1976-06-03 | 1981-02-04 | Res Inst Medicine Chem | Vitamin d derivatives |
| US4195027A (en) | 1978-01-16 | 1980-03-25 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
| JPS57149224A (en) | 1981-03-13 | 1982-09-14 | Chugai Pharmaceut Co Ltd | Tumor-suppressing agent |
| US4338250A (en) | 1981-04-27 | 1982-07-06 | Wisconsin Alumni Research Foundation | 1-Hydroxylation process |
| US4719204A (en) | 1984-03-05 | 1988-01-12 | Wisconsin Alumni Research Foundation | Fowl bone mineralization with 28-NOR 1α-hydroxyvitamin D2 analogs |
| US4554106A (en) | 1984-11-01 | 1985-11-19 | Wisconsin Alumni Research Foundation | Method for preparing 1α-hydroxyvitamin D compounds |
| IL78342A (en) | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| US5104864A (en) | 1988-08-02 | 1992-04-14 | Bone Care International, Inc. | Method for treating and preventing loss of bone mass |
| US5098899A (en) | 1989-03-06 | 1992-03-24 | Trustees Of Boston University | Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites |
| US4973584A (en) | 1989-03-09 | 1990-11-27 | Deluca Hector F | Novel 1α-hydroxyvitamin D2 epimer and derivatives |
| US5260290A (en) | 1990-02-14 | 1993-11-09 | Wisconsin Alumni Research Foundation | Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives |
| CA2069084C (en) | 1990-09-21 | 2007-05-22 | Joyce C. Knutson | 1.alpha.-hydroxy vitamin d4 and novel intermediates and analogues |
| US5763428A (en) | 1990-09-21 | 1998-06-09 | Bone Care International, Inc. | Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof |
| US6025346A (en) | 1990-09-21 | 2000-02-15 | Bone Care International, Inc. | 1α-hydroxy vitamin D4 and novel intermediates and analogues |
| US5801164A (en) | 1990-09-21 | 1998-09-01 | Bone Care International, Inc. | Methods of treating osteoporosis prophylactically or therapeutically |
| US5798345A (en) | 1990-09-21 | 1998-08-25 | Bone Care International, Inc. | Method of inhibiting the hyperproliferation of malignant cells |
| EP0550702B1 (en) | 1991-01-08 | 1999-05-06 | Bone Care International, Inc. | METHODS FOR PREPARATION AND USE OF 1$g(a),24-DIHYDROXY VITAMIN D 2? |
| US5786348A (en) | 1991-01-08 | 1998-07-28 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2 |
| US6166000A (en) | 1991-01-08 | 2000-12-26 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-Dihydroxy vitamin . D.sub2 |
| AU650751B2 (en) | 1991-05-28 | 1994-06-30 | Wisconsin Alumni Research Foundation | Novel synthesis of 19-nor vitamin D compounds |
| US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
| JP3179495B2 (ja) | 1992-08-28 | 2001-06-25 | ボーン ケア インターナショナル インコーポレイテッド | １α，２４（Ｓ）−ジヒドロキシビタミンＤ▲下２▼の調製及び使用方法 |
| US5763429A (en) | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
| FR2738745B1 (fr) * | 1995-09-15 | 1997-10-24 | Cird Galderma | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand de vdr et un retinoide, et leurs utilisations |
| DE19549243A1 (de) | 1995-12-21 | 1997-06-26 | Schering Ag | Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga |
| US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| AUPO727097A0 (en) | 1997-06-10 | 1997-07-03 | Unisearch Limited | Method of treatment of hepatoma and pharmaceutical compositions for use therein |
| US6087350A (en) | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| JP2002507415A (ja) | 1998-03-25 | 2002-03-12 | キュタノジェン， インコーポレイテッド | 癌の予防および処置のための方法 |
| CA2326117A1 (en) | 1998-03-27 | 1999-10-07 | Oregon Health Sciences University | Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders |
| US20010002396A1 (en) | 1998-07-16 | 2001-05-31 | Charles Achkar | Compositions and methods of treating skin conditions |
| NZ517978A (en) | 1999-09-29 | 2003-11-28 | Colotech As | Composition comprising ASA, calcium and 1,25 DHC for the prevention of colorectal cancer |
| CA2401304A1 (en) | 2000-03-02 | 2001-09-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Combination chemotherapy |
-
2001
- 2001-06-26 US US09/891,963 patent/US6538037B2/en not_active Expired - Fee Related
-
2002
- 2002-06-26 WO PCT/US2002/020317 patent/WO2003002110A1/en active IP Right Grant
- 2002-06-26 AU AU2002315463A patent/AU2002315463B2/en not_active Ceased
- 2002-06-26 JP JP2003508349A patent/JP2004535441A/ja active Pending
- 2002-06-26 EP EP02742318A patent/EP1408939A4/en not_active Withdrawn
- 2002-06-26 CA CA002451039A patent/CA2451039A1/en not_active Abandoned
- 2002-06-26 IL IL15906702A patent/IL159067A0/xx not_active IP Right Cessation
- 2002-06-26 KR KR10-2003-7016972A patent/KR20040011559A/ko not_active Application Discontinuation
- 2002-06-26 CN CNA028128362A patent/CN1520288A/zh active Pending
- 2002-06-26 MX MXPA03011306A patent/MXPA03011306A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004535441A5 (ja) | ||
| JP2004535429A5 (ja) | ||
| EP1383490B1 (en) | Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases | |
| EP1115391B1 (en) | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin | |
| CA2995025C (en) | Combination therapy with an antitumor alkaloid | |
| US20120107417A1 (en) | Effective Antitumor Treatments | |
| CA2582452C (en) | Pegylated liposomal doxorubicin in combination with ecteinascidin 743 | |
| Ajani et al. | A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma | |
| CA2450942A1 (en) | Method of treating hyperproliferative diseases using active vitamin d analogues | |
| RU2008138560A (ru) | Улучшенные способы лечения опухолей | |
| RU2391101C2 (ru) | Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений | |
| Heinemann et al. | High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline-and taxane-pretreated metastatic breast cancer | |
| AU2002212499A1 (en) | Compositions for antitumour treatment containing ecteinascidin 743 | |
| US20100009906A1 (en) | Anticancer Treatments | |
| JP2003533485A5 (ja) | ||
| CA2557504A1 (en) | Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor | |
| EP3151864A1 (en) | Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy | |
| US20060148752A1 (en) | Method of treating soild tumors and leukemias using combination therapy of vitamin D and anti-metabolic nucleoside analogs | |
| US20050026852A1 (en) | Method of augmenting the antitumor activity of anticancer agents | |
| Gore et al. | Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies | |
| US20110182909A1 (en) | Glufosfamide combination therapy | |
| Petruzelka et al. | Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy—results from an expanded access programme | |
| Ogle et al. | Radiation and chemotherapy in oral and maxillofacial surgery | |
| Papadimitriou et al. | Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study | |
| Polyzos et al. | Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel |